Juvenile Rheumatoid Arthritis

Phase 2

Completed

• Conditions: Juvenile Chronic Arthritis
• Interventions: Drug: Placebo; Drug: Anakinra

• Registration Number: NCT00037648
• Lead Sponsor: Amgen

Brief Summary

The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-07
• Study First Submitted: 2002-05-17
• Study First Submitted QC: 2002-05-17
• Study First Posted: 2002-05-20
• Primary Completion: 2003-11
• Study Completion: 2003-11
• Status Verified: 2008-02
• Last Update Submitted: 2009-11-25
• Last Update Posted: 2009-11-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	Placebo	-
anakinra	Anakinra	-

Primary Outcome Measures

Name	Time	Method
The primary outcome of the study was to evaluate the safety of anakinra	28 weeks